EA201492222A1 - Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии - Google Patents

Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии

Info

Publication number
EA201492222A1
EA201492222A1 EA201492222A EA201492222A EA201492222A1 EA 201492222 A1 EA201492222 A1 EA 201492222A1 EA 201492222 A EA201492222 A EA 201492222A EA 201492222 A EA201492222 A EA 201492222A EA 201492222 A1 EA201492222 A1 EA 201492222A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
methods
immunotherapy
nonalloactive
immunosupression
Prior art date
Application number
EA201492222A
Other languages
English (en)
Inventor
Роман Галетто
Аньес Губль
Стефани Гросс
Сесиль Манниуи
Лоран Пуаро
Эндрю Шаренберг
Джулианна Смит
Original Assignee
Селлектис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48579464&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селлектис filed Critical Селлектис
Publication of EA201492222A1 publication Critical patent/EA201492222A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)

Abstract

Способы разработка Т-клеток, полученных методами генной инженерии, для иммунотерапии, которые являются как неаллореактивными, так и устойчивыми к иммуносупрессорным лекарственным средствам. Настоящее изобретение относится к способам модификации Т-клеток путем инактивации как генов, кодирующих мишень иммуносупрессорного средства, так и Т-клеточного рецептора, в частности генов, кодирующих CD52 и TCR. Этот способ включает применение специфических редкощепящих эндонуклеаз, в частности TALE-нуклеаз (TAL-эффекторных эндонуклеаз) и полинуклеотидов, кодирующих такие полипептиды, для точно направленного выбора ключевых генов в Т-клетках, которые доступны от доноров или из культуры первичных клеток. Изобретение открывает путь к стандартным и доступным стратегиям адоптивной иммунотерапии для лечения рака и вирусных инфекций.
EA201492222A 2012-05-25 2013-05-13 Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии EA201492222A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651933P 2012-05-25 2012-05-25
US201261696612P 2012-09-04 2012-09-04
PCT/US2013/040755 WO2013176915A1 (en) 2012-05-25 2013-05-13 Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Publications (1)

Publication Number Publication Date
EA201492222A1 true EA201492222A1 (ru) 2015-05-29

Family

ID=48579464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492222A EA201492222A1 (ru) 2012-05-25 2013-05-13 Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии

Country Status (25)

Country Link
US (14) US11603539B2 (ru)
EP (6) EP3964567A1 (ru)
JP (5) JP6463671B2 (ru)
KR (2) KR102437522B1 (ru)
CN (3) CN104718284A (ru)
AR (1) AR096274A1 (ru)
AU (5) AU2013266733B2 (ru)
BR (1) BR112014029417B1 (ru)
CA (3) CA2874611C (ru)
DK (1) DK2855667T3 (ru)
EA (1) EA201492222A1 (ru)
ES (1) ES2962571T3 (ru)
HK (2) HK1208879A1 (ru)
HU (1) HUE064187T2 (ru)
IN (1) IN2014DN10991A (ru)
MA (1) MA37681B2 (ru)
MX (1) MX370265B (ru)
MY (1) MY180127A (ru)
NZ (1) NZ703281A (ru)
PL (1) PL2855667T3 (ru)
PT (1) PT2855667T (ru)
SG (2) SG11201407802WA (ru)
UA (1) UA118652C2 (ru)
WO (2) WO2013176916A1 (ru)
ZA (1) ZA201409536B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365226B2 (en) 2016-09-08 2022-06-21 2Seventy Bio, Inc. PD-1 homing endonuclease variants, compositions, and methods of use
RU2781083C2 (ru) * 2016-09-08 2022-10-05 2сэвэнти био, Инк. Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1

Families Citing this family (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2013176916A1 (en) * 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
HUE050797T2 (hu) * 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T-sejt módosító vegyületek és alkalmazásaik
JP6450690B2 (ja) 2013-02-15 2019-01-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キメラ抗原受容体及びその使用方法
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
JP6541639B2 (ja) * 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｔ細胞増殖をコントロールするための方法
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
JP6005572B2 (ja) * 2013-03-28 2016-10-12 Kddi株式会社 動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、およびプログラム
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
DK2997134T3 (da) 2013-05-14 2020-09-28 Univ Texas Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
AU2014351871B2 (en) * 2013-11-22 2020-02-13 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
AU2014351797B2 (en) * 2013-11-22 2021-03-11 Cellectis Method of engineering chemotherapy drug resistant T-cells for immunotherapy
RU2689558C1 (ru) * 2013-11-22 2019-05-28 Селлектис Способ конструирования аллогенных и устойчивых к лекарственным препаратам т-клеток для иммунотерапии
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10239948B2 (en) * 2013-12-20 2019-03-26 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
CA2936693C (en) * 2014-01-14 2020-07-21 Cellectis Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
CN111705365A (zh) 2014-02-11 2020-09-25 科罗拉多州立大学董事会（法人团体） Crispr支持的多路基因组工程化
EP3505623A1 (en) * 2014-02-14 2019-07-03 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CA2938887C (en) * 2014-02-14 2023-04-11 Laurence J. N. Cooper Chimeric antigen receptors and methods of making
CA2937750A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3107552B1 (en) * 2014-02-21 2018-03-28 Cellectis Method for in situ inhibition of regulatory t cells
SG11201606583VA (en) * 2014-03-05 2016-09-29 Ucl Business Plc Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
PL3116902T3 (pl) 2014-03-11 2020-07-27 Cellectis Sposób wytwarzania limfocytów T kompatybilnych do przeszczepienia alogenicznego
RU2727290C2 (ru) 2014-03-19 2020-07-21 Селлектис Cd123-специфические химерные антигенные рецепторы для иммунотерапии рака
CN106795221B (zh) 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
AU2015245469B2 (en) * 2014-04-11 2020-11-12 Cellectis Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
EP3132030B1 (en) * 2014-04-18 2020-08-26 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015166056A1 (en) 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
JP7113618B2 (ja) 2014-07-15 2022-08-05 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法用の操作された細胞
CN106922148B (zh) 2014-07-29 2021-10-15 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
US9546206B2 (en) * 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
EP3189148A4 (en) * 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
WO2016034666A1 (en) 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20170354681A1 (en) * 2014-10-24 2017-12-14 Bcrt Holding Bv T cell-based immunotherapeutics
EP3215168B1 (en) * 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
GB201421096D0 (en) * 2014-11-27 2015-01-14 Imp Innovations Ltd Genome editing methods
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
EP3250606B1 (en) 2015-01-26 2020-11-25 Cellectis Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
KR101755431B1 (ko) * 2015-02-02 2017-07-12 단국대학교 산학협력단 키메릭 항원 수용체(Chimeric antigen receptor) 전달용 CTLA-4 타겟팅 트랜스-스플라이싱 라이보자임 및 이의 용도
AU2016214301B2 (en) * 2015-02-06 2022-05-19 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN108064283B (zh) 2015-02-24 2024-01-09 加利福尼亚大学董事会 结合触发的转录开关及其使用方法
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
JP2018509148A (ja) 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
AU2016235388B2 (en) * 2015-03-20 2022-02-03 Children's National Medical Center Generating virus or other antigen-specific T cells from a naive T cell population
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016166268A1 (en) 2015-04-17 2016-10-20 Cellectis Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
EP3317399A1 (en) 2015-06-30 2018-05-09 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US10450585B2 (en) * 2015-07-13 2019-10-22 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US20170014449A1 (en) * 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CN108472314A (zh) 2015-07-31 2018-08-31 明尼苏达大学董事会 修饰的细胞和治疗方法
US10709775B2 (en) 2015-08-11 2020-07-14 Cellectis Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
EP3340998B1 (en) * 2015-08-28 2023-01-11 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
EP3340995A4 (en) 2015-08-28 2019-04-03 The Trustees Of The University Of Pennsylvania METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE
JP6929837B2 (ja) 2015-10-05 2021-09-15 プレシジョン バイオサイエンシズ，インク． ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ
CN108601821B (zh) * 2015-10-05 2023-09-19 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017070429A1 (en) * 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
JP7092662B2 (ja) * 2015-10-30 2022-06-28 チルドレンズ ナショナル メディカル センター ナイーブｔ細胞集団からのｈｐｖ抗原特異的ｔ細胞の生成
CN108473961B (zh) 2015-11-04 2022-11-29 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
CA3003150A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
CA3004421A1 (en) * 2015-11-05 2017-05-11 Baylor College Of Medicine An efficient, scalable patient-derived xenograft system based on a chick chorioallantoic membrane (cam) in vivo model
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017106528A2 (en) * 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
CN105505869A (zh) * 2015-12-21 2016-04-20 河南大学淮河医院 一种针对肿瘤干细胞的嵌合抗原受体t细胞
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
SG11201804038VA (en) 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
BR112018068354A2 (pt) * 2016-03-11 2019-01-15 Bluebird Bio Inc células efetoras imunológicas do genoma editado
CN109415687A (zh) * 2016-04-07 2019-03-01 蓝鸟生物公司 嵌合抗原受体t细胞组合物
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US20190328783A1 (en) 2016-04-15 2019-10-31 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
EP3429633B1 (en) 2016-04-15 2021-02-24 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
KR20180135460A (ko) * 2016-04-15 2018-12-20 자임워크스 인코포레이티드 면역치료제를 표적으로 하는 다중-특이적 항원-결합 작제물
JP7058223B2 (ja) 2016-04-15 2022-04-21 メモリアル スローン ケタリング キャンサー センター トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3474669B1 (en) 2016-06-24 2022-04-06 The Regents of The University of Colorado, A Body Corporate Methods for generating barcoded combinatorial libraries
WO2018007263A1 (en) 2016-07-06 2018-01-11 Cellectis Sequential gene editing in primary immune cells
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
SG10201913315SA (en) 2016-08-24 2020-02-27 Sangamo Therapeutics Inc Regulation of gene expression using engineered nucleases
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201901364VA (en) * 2016-08-24 2019-03-28 Sangamo Therapeutics Inc Engineered target specific nucleases
CN109843922B (zh) 2016-09-02 2023-10-03 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
CA3036972A1 (en) 2016-09-14 2018-03-22 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
US10961505B2 (en) 2016-10-05 2021-03-30 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
PT3445787T (pt) 2016-10-07 2021-03-15 Tcr2 Therapeutics Inc Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MX2019004156A (es) * 2016-10-11 2019-09-26 Bluebird Bio Inc Variantes de endonucleasa homing de receptor de linfocitos t alfa (tcralpha).
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
US11873511B2 (en) * 2016-10-19 2024-01-16 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
WO2018087276A1 (en) 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 modulators and uses thereof
EP3321280B8 (en) 2016-11-10 2021-03-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Immune modulators for reducing immune-resistance in melanoma and other proliferative diseases
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
JP2020513775A (ja) * 2017-01-10 2020-05-21 ザ ジェネラル ホスピタル コーポレイション 修飾されたｔ細胞及びその使用方法
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110446781A (zh) * 2017-02-15 2019-11-12 蓝鸟生物公司 供体修复模板多重基因组编辑
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CN110678197A (zh) 2017-03-15 2020-01-10 牛津生物医学（英国）有限公司 方法
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
MX2019011475A (es) 2017-03-31 2019-12-16 Cellectis Celulas inmunes universales manipuladas para ser dotadas con receptor de antigeno quimerico anti-cd22.
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
AU2018251150B2 (en) 2017-04-13 2024-05-09 Albert-Ludwigs-Universität Freiburg New sequence specific reagents targeting CCR5 in primary hematopoietic cells
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
DK3391907T3 (da) 2017-04-20 2020-03-09 Iomx Therapeutics Ag Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
IL270415B1 (en) 2017-05-12 2024-04-01 Crispr Therapeutics Ag Materials and methods for cell engineering and their uses in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2019014960A (es) * 2017-06-12 2020-08-06 Obsidian Therapeutics Inc Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
US20210139870A1 (en) 2017-06-19 2021-05-13 Cellectis Anti-hbv combination therapies involving specific endonucleases
DK3538645T3 (da) 2017-06-20 2021-04-19 Inst Curie Immunceller der mangler suv39h1
AU2018288863A1 (en) * 2017-06-22 2020-01-30 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
JP2020530277A (ja) * 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ 反復投与のための細胞免疫療法
WO2019005957A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019011118A1 (zh) 2017-07-14 2019-01-17 苏州克睿基因生物科技有限公司 一种基因编辑***及基因编辑的方法
KR20200028447A (ko) 2017-07-17 2020-03-16 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
WO2019016360A1 (en) 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
CA3069557A1 (en) 2017-07-21 2019-01-24 Cellectis Engineered immune cells resistant to tumor microoenvironment
CA3070998A1 (en) * 2017-07-25 2019-01-31 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3684408A1 (en) 2017-09-19 2020-07-29 Massachusetts Institute of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
CN111511388A (zh) 2017-09-21 2020-08-07 博德研究所 用于靶向核酸编辑的***、方法和组合物
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CA3084476A1 (en) 2017-10-19 2019-04-25 Cellectis Targeted gene integration of nk inhibitors genes for improved immune cells therapy
KR20200094147A (ko) 2017-10-31 2020-08-06 알로젠 테라퓨틱스 인코포레이티드 동종이계 키메라 항원 수용체 t 세포를 투여하기 위한 방법 및 조성물
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
CN111601883A (zh) 2017-11-17 2020-08-28 艾欧凡斯生物治疗公司 由细针抽吸物和小活检物扩增til
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
WO2019106163A1 (en) 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
EP3728563A4 (en) 2017-12-22 2021-11-10 Fate Therapeutics, Inc. ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
US20190194617A1 (en) * 2017-12-22 2019-06-27 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
WO2019129850A1 (en) 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
EP3684399A1 (en) 2017-12-29 2020-07-29 Cellectis Method for improving production of car t cells
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
GB201801920D0 (en) * 2018-02-06 2018-03-21 Autolus Ltd Polypeptides and methods
SG11202007622SA (en) * 2018-02-11 2020-09-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
AU2019231792A1 (en) * 2018-03-09 2020-10-22 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20210017248A1 (en) * 2018-03-16 2021-01-21 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
MX2020009896A (es) 2018-03-29 2020-10-12 Fate Therapeutics Inc Celulas efectoras inmunitarias modificadas y usos de las mismas.
JP2021520211A (ja) 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
JP7304888B2 (ja) 2018-04-12 2023-07-07 プレシジョン バイオサイエンシズ，インク． ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
CA3098303A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
WO2020007593A1 (en) 2018-07-02 2020-01-09 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
BR112021000919A2 (pt) 2018-07-19 2021-04-27 Regeneron Pharmaceuticals, Inc. receptores de antígenos quiméricos com especificidade bcma e usos dos mesmos
WO2020020359A1 (en) * 2018-07-26 2020-01-30 Nanjing Legend Biotech Co., Ltd. Nef-containing t cells and methods of producing thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US20210355522A1 (en) 2018-08-20 2021-11-18 The Broad Institute, Inc. Inhibitors of rna-guided nuclease activity and uses thereof
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
MX2021004953A (es) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Seleccion de celulas t reactivas al tumor mejoradas.
EP3877511A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
KR20210091213A (ko) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
EP3876957A1 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
JP2022513652A (ja) 2018-11-28 2022-02-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 機能および抑制性環境に対する抵抗性を増強するための免疫細胞のマルチプレックスゲノム編集
JP2022513665A (ja) 2018-11-29 2022-02-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞のエクスビボ増殖のための方法およびその使用方法
EP3887507A1 (en) 2018-11-30 2021-10-06 Janssen Biotech, Inc. Gamma delta t cells and uses thereof
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
EP3931310A1 (en) 2019-03-01 2022-01-05 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020191153A2 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP4332115A3 (en) 2019-04-03 2024-05-29 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
FI3959235T3 (fi) * 2019-04-26 2023-09-27 Allogene Therapeutics Inc Rituksimabiresistenttejä kimeerisiä antigeenireseptoreja ja niiden käyttö
WO2020222176A1 (en) 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
EP3736330A1 (en) 2019-05-08 2020-11-11 European Molecular Biology Laboratory Modified adeno-associated virus (aav) particles for gene therapy
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
EP3976073A4 (en) * 2019-06-01 2023-08-02 Sivec Biotechnologies, LLC BACTERIAL PLATFORM FOR DELIVERING GENE EDITING SYSTEMS TO EUKARYOT CELLS
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
JP2022538688A (ja) 2019-07-05 2022-09-05 イオックス セラピューティクス アーゲー ＩＧＳＦ１１（ＶＳＩＧ３）のＩｇＣ２に結合する抗体及びその使用
CA3146895A1 (en) 2019-07-23 2021-01-28 Mnemo Therapeutics Immune cells defective for suv39h1
CA3147903A1 (en) 2019-07-24 2021-01-28 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20220273720A1 (en) * 2019-08-20 2022-09-01 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
BR112022003471A2 (pt) 2019-08-27 2022-05-24 Janssen Biotech Inc Sistema receptor de antígeno quimérico e usos do mesmo
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11723950B2 (en) 2019-10-18 2023-08-15 Trustees Of Boston University CAL-T constructs and uses thereof
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20230000915A1 (en) * 2019-11-25 2023-01-05 Kyoto University T-cell master cell bank
JP2023504081A (ja) * 2019-11-27 2023-02-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽細胞腫及び他の癌を処置するためのナチュラルキラー細胞免疫療法
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4073236A1 (en) 2019-12-11 2022-10-19 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3166356A1 (en) 2019-12-23 2021-07-01 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
KR20220141299A (ko) 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
EP4110805A1 (en) 2020-02-24 2023-01-04 Allogene Therapeutics, Inc. Bcma car-t cells with enhanced activities
JOP20220206A1 (ar) 2020-03-03 2023-01-30 Janssen Biotech Inc الخلايا التائية واستخداماتها
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
AU2021236145A1 (en) 2020-03-10 2022-09-22 Dana-Farber Cancer Institute, Inc. Methods for generating engineered memory-like NK cells and compositions thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
JP2023523855A (ja) 2020-05-04 2023-06-07 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
JP2023525513A (ja) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム 細胞ゲノムにおける外因性配列の標的化挿入のための方法
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
EP3910331A1 (en) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
US20230228739A1 (en) 2020-07-03 2023-07-20 Cellectis S.A. Method for determining potency of chimeric antigen receptor expressing immune cells
EP4175668A1 (en) 2020-07-06 2023-05-10 iOmx Therapeutics AG Antibodies binding igv of igsf11 (vsig3) and uses thereof
JP2023535371A (ja) 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
WO2022018262A1 (en) 2020-07-24 2022-01-27 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
CN116096864A (zh) 2020-07-30 2023-05-09 居里研究所 Socs1缺陷的免疫细胞
WO2022023529A1 (en) 2020-07-31 2022-02-03 Cellectis S.A. Dual car-t cells
WO2022031597A1 (en) 2020-08-03 2022-02-10 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
EP4196231A1 (en) 2020-08-14 2023-06-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Chimeric antigen receptor t cells for treating autoimmunity
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
EP4244209A1 (en) 2020-11-11 2023-09-20 European Molecular Biology Laboratory Modified viral particles for gene therapy
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4251746A1 (en) 2020-11-30 2023-10-04 Cellectis SA Use of aminoquinoline compounds for higher gene integration
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4262811A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024500403A (ja) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球によるがんの治療
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体***
WO2022135457A1 (zh) * 2020-12-23 2022-06-30 广东菲鹏制药股份有限公司 一种抗pd-l1抗体及其应用
TW202242117A (zh) 2020-12-30 2022-11-01 美商亞勞諾斯醫療公司 包含多順反子表現卡匣之重組載體及其使用方法
JP2024506557A (ja) 2021-01-29 2024-02-14 アイオバンス バイオセラピューティクス，インコーポレイテッド 修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2022198141A1 (en) 2021-03-19 2022-09-22 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CN118019546A (zh) 2021-03-23 2024-05-10 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
BR112023021665A2 (pt) 2021-04-19 2023-12-19 Iovance Biotherapeutics Inc Método para tratar um câncer, e, composição
EP4330288A1 (en) 2021-04-30 2024-03-06 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
WO2022235662A1 (en) 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
CA3219148A1 (en) 2021-05-17 2022-11-24 Frederick G. Vogt Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2024519041A (ja) 2021-05-21 2024-05-08 セレクティス ソシエテ アノニム 固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強
IL308468A (en) 2021-06-15 2024-01-01 Allogene Therapeutics Inc Selective Targeting of Host CD70+ ALLOREACTIVE Cells to Extend Allogeneic CAR T Cell Persistence
WO2023004074A2 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
WO2023007431A1 (en) 2021-07-29 2023-02-02 Takeda Pharmaceutical Company Limited Engineered immune cell that specifically targets mesothelin and uses thereof
CA3228262A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
IL311333A (en) 2021-09-09 2024-05-01 Iovance Biotherapeutics Inc Processes for the production of TIL products using a strong PD-1 TALEN
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
AU2022395500A1 (en) 2021-11-23 2024-05-23 Cellectis Sa New tale protein scaffolds with improved on-target/off-target activity ratios
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023233003A1 (en) 2022-06-03 2023-12-07 Cellectis Sa Tale base editors for gene and cell therapy
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
WO2024022509A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Methods for promoting persistence of cell therapy
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024094775A1 (en) 2022-11-03 2024-05-10 Cellectis S.A. Enhancing efficacy and safety of t-cell-mediated immunotherapy
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
CN116284370B (zh) * 2023-02-27 2024-05-28 南京立顶医疗科技有限公司 一种多聚体糖化血红蛋白单克隆抗体及制备方法
CN116987699A (zh) * 2023-09-05 2023-11-03 深圳市艾迪贝克生物医药有限公司 用于制备通用型car-t细胞的基因片段、其工具***及应用
CN117164714B (zh) * 2023-10-08 2024-04-23 北京奇迈永华生物科技有限公司 一种靶向bcma的抗体及其应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US5770396A (en) 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US5766944A (en) * 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
KR20010083111A (ko) * 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
US6673594B1 (en) * 1998-09-29 2004-01-06 Organ Recovery Systems Apparatus and method for maintaining and/or restoring viability of organs
MXPA02000192A (es) * 1999-06-30 2004-08-12 Corixa Corp Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
MXPA02008265A (es) 2000-02-24 2004-09-10 Xcyte Therapies Inc Concentracion y estimulacion simultanea de calulas.
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
CN1630664A (zh) 2001-09-04 2005-06-22 耶达研究发展有限公司 胱冬酶－8结合蛋白及其制备和使用
US20050130125A1 (en) 2002-03-04 2005-06-16 Yuly Zagyansky End of aids for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end
CA2484989A1 (en) * 2002-05-02 2003-11-27 The Washington University Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7496848B2 (en) 2002-07-22 2009-02-24 Konica Corporation Image forming apparatus and image forming system
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
WO2004083379A2 (en) 2003-03-14 2004-09-30 Walters Richard E Large volume ex vivo electroporation method
WO2004087210A1 (ja) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha 抗cd52抗体による調節性t細胞分化誘導･増殖方法およびそのための医薬組成物
WO2005062893A2 (en) * 2003-12-22 2005-07-14 Genzyme Corporation Anti-cd52 antibody treatment for diabetes
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
CA2616069C (en) * 2005-08-03 2018-07-31 Therapeutic Human Polyclonals, Inc. Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin
EP2594591B1 (en) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
JPWO2007043200A1 (ja) * 2005-09-30 2009-04-16 独立行政法人理化学研究所 Ｔ細胞分化調節剤
WO2007063075A1 (en) * 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
WO2008022152A2 (en) 2006-08-14 2008-02-21 Xencor, Inc. Optimized antibodies that target cd19
EP2089427B1 (en) * 2006-11-13 2014-07-30 Sangamo BioSciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
WO2008093688A1 (ja) * 2007-01-30 2008-08-07 Forerunner Pharma Research Co., Ltd. キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法
US8563314B2 (en) * 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
CA2734908A1 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
KR101825457B1 (ko) * 2008-10-08 2018-02-05 캠브리지 엔터프라이즈 리미티드 다발경화증에 대한 2차 자가면역 질환의 진단 및 치료를 위한 방법 및 조성물
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US9181525B2 (en) * 2009-03-06 2015-11-10 Mie University Method for enhancing a function of a T cell
WO2010111490A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010132697A2 (en) * 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
US20110027881A1 (en) * 2009-07-31 2011-02-03 St. Marianna University School Of Medicine Production method of immune cells
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP2510096B2 (en) * 2009-12-10 2018-02-07 Regents of the University of Minnesota Tal effector-mediated dna modification
CA2798988C (en) * 2010-05-17 2020-03-10 Sangamo Biosciences, Inc. Tal-effector (tale) dna-binding polypeptides and uses thereof
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
JP2013534423A (ja) * 2010-07-07 2013-09-05 セレクティス Ｎａｎｏｇ遺伝子中のｄｎａ標的配列を切断するメガヌクレアーゼバリアント及びその使用
JP6050230B2 (ja) * 2010-07-21 2016-12-21 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｈｌａ遺伝子座の修飾のための方法及び組成物
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
US20130337454A1 (en) 2010-10-27 2013-12-19 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
EA201391059A1 (ru) 2011-01-18 2014-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции для лечения рака и способы их применения
EP3450563A1 (en) * 2011-02-25 2019-03-06 Recombinetics, Inc. Genetically modified animals and methods for making the same
ES2841983T3 (es) 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
EP3320910A1 (en) 2011-04-05 2018-05-16 Cellectis Method for the generation of compact tale-nucleases and uses thereof
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
TWI496886B (zh) * 2011-06-24 2015-08-21 Taipei Veteran General Hospital 提升感染性與惡性疾病之治療之免疫反應
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
CN107266584B (zh) 2011-07-29 2022-05-13 宾夕法尼亚大学董事会 转换共刺激受体
AU2012308205A1 (en) * 2011-09-16 2014-03-13 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
AU2012325915A1 (en) * 2011-10-20 2014-04-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
JP6144691B2 (ja) * 2011-11-16 2017-06-07 サンガモ セラピューティクス， インコーポレイテッド 修飾されたｄｎａ結合タンパク質およびその使用
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
KR20210134808A (ko) 2011-12-05 2021-11-10 팩터 바이오사이언스 인크. 세포를 형질감염시키는 방법들 및 생성물들
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013176916A1 (en) 2012-05-25 2013-11-28 Roman Galetto Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
EP3187586B1 (en) * 2012-08-05 2019-09-25 Absci, LLC Inducible coexpression system
SG11201501471VA (en) 2012-09-04 2015-03-30 Cellectis Multi-chain chimeric antigen receptor and uses thereof
HUE050797T2 (hu) * 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T-sejt módosító vegyületek és alkalmazásaik
EP2919799B1 (en) * 2012-11-15 2021-02-24 The Walter and Eliza Hall Institute of Medical Research Soluble mediator
JP6450690B2 (ja) * 2013-02-15 2019-01-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア キメラ抗原受容体及びその使用方法
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
EP4364809A2 (en) 2013-05-13 2024-05-08 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
WO2016094880A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
CN108601821B (zh) 2015-10-05 2023-09-19 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
AU2016348782A1 (en) * 2015-11-05 2018-05-31 Cellectis Process of gene-editing of cells isolated from a subject suffering from a metabolic disease affecting the erythroid lineage, cells obtained by said process and uses thereof.
WO2017105110A1 (ko) 2015-12-15 2017-06-22 (주)옵토마인드 광 케이블용 송수신 장치 및 그 정렬 방법
US20190032088A1 (en) * 2016-02-26 2019-01-31 Cellectis Micelle based system nuclease encapsulation for in-vivo gene editing
WO2019016360A1 (en) * 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
US20230158070A1 (en) * 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365226B2 (en) 2016-09-08 2022-06-21 2Seventy Bio, Inc. PD-1 homing endonuclease variants, compositions, and methods of use
RU2781083C2 (ru) * 2016-09-08 2022-10-05 2сэвэнти био, Инк. Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1
US11912746B2 (en) 2016-09-08 2024-02-27 2Seventy Bio, Inc. PD-1 homing endonuclease variants, compositions, and methods of use

Also Published As

Publication number Publication date
PT2855667T (pt) 2023-11-22
US10342829B2 (en) 2019-07-09
CA2874609C (en) 2021-12-07
AU2013266734B2 (en) 2018-11-22
EP3276000A3 (en) 2018-02-21
CA3133545C (en) 2023-08-08
JP6463671B2 (ja) 2019-02-06
KR102247979B1 (ko) 2021-05-04
EP2855667A1 (en) 2015-04-08
AU2013266733A1 (en) 2015-01-15
MA37681A3 (fr) 2018-06-29
WO2013176916A1 (en) 2013-11-28
NZ703281A (en) 2017-01-27
US11274316B2 (en) 2022-03-15
SG11201407802WA (en) 2015-01-29
JP2015525065A (ja) 2015-09-03
CN104718284A (zh) 2015-06-17
BR112014029417A2 (ru) 2017-08-15
AU2021201967A1 (en) 2021-04-29
MX2014014364A (es) 2015-09-22
US20220177914A1 (en) 2022-06-09
MY180127A (en) 2020-11-23
US20180021379A1 (en) 2018-01-25
EP2855667B1 (en) 2023-08-09
EP2855666A1 (en) 2015-04-08
US20130315884A1 (en) 2013-11-28
KR20210050590A (ko) 2021-05-07
PL2855667T3 (pl) 2024-03-25
KR20150029651A (ko) 2015-03-18
JP2018183167A (ja) 2018-11-22
US10363270B2 (en) 2019-07-30
MA37681A2 (fr) 2016-06-30
CA2874611A1 (en) 2013-11-28
CA3133545A1 (en) 2013-11-28
KR102437522B1 (ko) 2022-08-26
US20140134142A1 (en) 2014-05-15
HK1245321A1 (zh) 2018-08-24
ES2962571T3 (es) 2024-03-19
JP2019058189A (ja) 2019-04-18
US20150203817A1 (en) 2015-07-23
US11891614B2 (en) 2024-02-06
US20200281979A1 (en) 2020-09-10
EP2855666B1 (en) 2019-12-04
HUE064187T2 (hu) 2024-02-28
AU2021201200B2 (en) 2023-10-19
AU2021201200A1 (en) 2021-03-11
MA37681B2 (fr) 2020-07-29
CA2874611C (en) 2023-01-24
US10874693B2 (en) 2020-12-29
JP6463672B2 (ja) 2019-02-06
US20220348955A1 (en) 2022-11-03
US11007224B2 (en) 2021-05-18
BR112014029417B1 (pt) 2023-03-07
AU2018236867B2 (en) 2021-01-21
HK1208879A1 (en) 2016-03-18
AU2018236867A1 (en) 2018-10-18
US20160145337A1 (en) 2016-05-26
US20210220405A1 (en) 2021-07-22
JP2018011603A (ja) 2018-01-25
US10286007B2 (en) 2019-05-14
EP3276000A2 (en) 2018-01-31
AU2013266733B2 (en) 2018-07-05
EP3279315A3 (en) 2018-02-28
CN108998418A (zh) 2018-12-14
CA2874609A1 (en) 2013-11-28
US11603539B2 (en) 2023-03-14
ZA201409536B (en) 2022-11-30
MX370265B (es) 2019-12-09
JP6991167B2 (ja) 2022-02-03
WO2013176915A1 (en) 2013-11-28
US20190216853A1 (en) 2019-07-18
US20180360883A1 (en) 2018-12-20
JP6655049B2 (ja) 2020-02-26
JP2015523064A (ja) 2015-08-13
CN111676196A (zh) 2020-09-18
AR096274A1 (es) 2015-12-16
DK2855667T3 (da) 2023-10-30
WO2013176916A8 (en) 2014-10-16
SG10201806573TA (en) 2018-09-27
EP3964567A1 (en) 2022-03-09
EP3279315A2 (en) 2018-02-07
US20190216854A1 (en) 2019-07-18
AU2013266734A1 (en) 2015-01-15
EP3473707A1 (en) 2019-04-24
US20210060080A1 (en) 2021-03-04
US11414674B2 (en) 2022-08-16
JP7257749B2 (ja) 2023-04-14
US20170360835A1 (en) 2017-12-21
US10517896B2 (en) 2019-12-31
US10426795B2 (en) 2019-10-01
UA118652C2 (uk) 2019-02-25
IN2014DN10991A (ru) 2015-09-25

Similar Documents

Publication Publication Date Title
EA201492222A1 (ru) Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии
MX2015015639A (es) Métodos para manipular células t alogénicas, altamente activas para inmunoterapia.
MX2015015638A (es) Metodos para diseñar celulas t altamente activas para inmunoterapia.
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
EA201790953A1 (ru) Изменение экспрессии гена в cart-клетках и их применения
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MX2018003534A (es) Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
CR20170032A (es) Moleculas biespecíficas de unión a antígeno activadoras de células t
MX2017007744A (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
MX2017006571A (es) Moleculas de union a antigeno biespecificas activadoras de celulas t.
EA201400254A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
BR112014019579A8 (pt) Anticorpos, polinucleotídeos, vetores, métodos de produção de um anticorpo, heteromultímero, método de produção de um heteromultímero e célula hospedeira
GB2548059A (en) Induced hepatocytes and uses thereof
EP4297036A3 (en) Method for predicting the off-target binding of a peptide which binds to a target peptide presented by a major histocompatibility complex
EA201890782A1 (ru) Способ перенацеливания t-клеток для лечения инфекции hiv
MX2019002998A (es) Celulas t con resistencia incrementada a la inmunosupresion.
MY175935A (en) Method for activating helper t cell
MX2016016142A (es) Metodos de cultivo por perfusion y usos de los mismos.
BR112012012911A8 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo capaz de ligar cd4, para a produção de um anticorpo ou fragmento de anticorpo in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.
MX342322B (es) Compuestos organicos.
EA201892452A1 (ru) T-клеточные рецепторы и варианты их применения